Agilent Technologies Thought Leader Award Supports Institut Curie, Dr.
Emmanuel Barillot’s Web-Based Tools for Cancer and Drug-Safety Research
SANTA CLARA, Calif. -- August 27, 2013
Agilent Technologies Inc. (NYSE: A) today announced that Dr. Emmanuel
Barillot, director of Bioinformatics and Systems IT at the Institut Curie in
Paris, has received an Agilent Thought Leader Award in recognition of his
pioneering development of user-friendly, Web-based bioinformatics tools for
The award will support Dr. Barillot’s work in developing a database of
cellular signaling pathways and a visualization tool to help the
pharmaceutical industry develop more effective cancer treatments.
The new Web-based visualization tool will augment the institute’s Atlas of
Cancer Signaling Networks and will be further enhanced by the combined
capabilities of Curie’s NaviCell mapping tool and Agilent’s GeneSpring
software and NMR technologies. Together, these tools will enable researchers
to identify off-pathway effects that could lead to undesirable outcomes, such
as DNA damage.
“Assessing the safety and potential toxicity of drug candidates is a
significant hurdle in the extraordinarily complex, labor-intensive drug
development process,” said Tony Owen, Agilent’s senior director of life
science marketing and market development. “Pharmaceutical companies can spend
many years and billions of dollars only to find that a once-promising
preclinical therapeutic compound is actually harmful to patients in clinical
tests. It is incumbent upon drug developers to find ways to assess drug
toxicity much earlier in the process to reduce R&D time, minimize costs and
maximize patient benefits.”
“The Agilent Thought Leader Award will accelerate the further development of
the Curie Atlas of Cancer Signaling Networks, a comprehensive and freely
available cancer pathway database, and NaviCell network visualization tool,”
said Dr. Barillot. “These tools will enable earlier identification and
visualization of toxic interactions between signaling pathways during the
discovery and development of therapeutics for the treatment of cancer, thus
enabling better informed drug-candidate selection and prioritization. They
will also be useful for interpreting high-throughput biological data, like
next-generation sequencing profiles of tumors or other samples.”
The Agilent Thought Leader program promotes fundamental scientific advances by
contributing financial support, products and expertise to the research of
influential thought leaders in the life sciences and chemical analysis.
Information about previous award recipients is available at
About the Institut Curie
The Institut Curie comprises the largest oncology research center and two
state-of-the-art hospitals in France. A pioneer of many cancer treatments, the
Institut Curie is a center of excellence for the treatment of breast cancer,
pediatric tumors and ocular tumors, and is responsible for medical and
scientific innovations in France and abroad.
Founded in 1909 on a model devised by Marie Curie, the institute has 3,200
researchers, physicians, clinicians, technicians and administrative staff. For
more information, visit www.curie.fr.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company
and a technology leader in chemical analysis, life sciences, diagnostics,
electronics and communications. The company’s 20,500 employees serve customers
in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal
2012. Information about Agilent is available at www.agilent.com.
NOTE TO EDITORS: Further technology, corporate citizenship and executive news
is available at www.agilent.com/go/news.
Agilent Technologies Inc.
Susan Berg, +1 408-553-7093
Press spacebar to pause and continue. Press esc to stop.